| Ytd | 53.89% | |
| 1y | -26.22% |
| Open | 0.78 | Prev Close | 0.81 | Low | 0.78 | High | 0.90 | Mkt Cap | 14.88M |
| Vol | 5.41M | Avg Vol | 676.49K | EPS | -0.66 | P/E | -1.35 | Forward P/E | -2.95 |
| Beta | 2.00 | Short Ratio | 0.65 | Inst. Own | 51.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.68 | 200-d Avg | 0.56 | 1yr Est | 6.19 |
VYNE News
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Co
Crown Holdings Inc (CCK) stock gained 16.4% in pre-market trading after reporting strong Q2 results
Gainers VYNE Therapeutics (NASDAQ:VYNE) stock increased by 17.9% to $0.79 during Friday's pre-m
VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that
Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share Aggregate cas
VYNE Therapeutics Inc. (NASDAQ: VYNE - Get Free Report) was the recipient of a significant decrease
VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) and Vivani Medical (NASDAQ: VANI - Get Free Repor
VYNE Therapeutics Inc. (NASDAQ: VYNE - Get Free Report) was the target of a large drop in short inte
MILWAUKEE , Dec. 18, 2025 /PRNewswire/ -- The Ademi Firm is investigating VYNE (Nasdaq: VYNE) for po
NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Ass
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”) and Yarro
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.17 per share versus the Zacks Con
Company is progressing its previously initiated strategic review evaluating a range of options to ma
Savara (NASDAQ: SVRA - Get Free Report) and VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) are b
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.13 per share versus the Zacks Con
BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” o
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Sta
BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” o
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway
The U.S. Food and Drug Administration (FDA) on Friday verbally informed that it placed a clinical ho
BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”
On Thursday, 930 stocks hit new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
When insiders purchase or sell shares, it indicates their confidence or concern around the company&#
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 o
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report